Anti-Leucine-Rich, Glioma-Inactivated Protein 1 (LGI1), Serum
Use
Leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis is a rare autoimmune voltage-gated potassium channel complex (VGKC) antibody-associated limbic encephalitis. Specifically, it is classified as an ant neuronal surface antigen- or ant synaptic protein-associated autoimmune encephalitis. In addition to the common symptoms of limbic encephalitis such as cognitive impairment, seizures, and psychiatric disorders, this disease is also associated with faciobrachial dystonic seizure (FBDA) and refractory hyponatremia. Unlike other limbic encephalirides, LGI1 antibody encephalitis is rarly accompanied by tumors and shows a good response to immunotherapy.
Special Instructions
Not provided.
Limitations
Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure. The test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Immunoassay (Immunofluorescence)
Biomarkers
LGI1 Antibody
Protein
LOINC Codes
- 94288-8 - LGI1 IgG CSF Ql CBA IFA
- 82978-8 - LGI1 IgG SerPl Ql IF
- 90831-9 - LGI1 Ab Titr CSF CBA IFA
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Gel-barrier tube, red-top tube, serum gel tube, serum transfer tube
Storage Instructions
Room temperature
Causes for Rejection
CSF or plasma; contaminated, hemolyzed, or severely lipemic specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant